Compare Merck & Co., Inc. (MRK) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs NetEase Inc — how do they compare? Merck & Co., Inc. trades at $148.18 (market cap $366.28B), while NetEase Inc trades at $115.64 (market cap $76.85B). The key difference: Merck & Co., Inc. is far larger — about 4.8× NetEase Inc's market cap, and NetEase Inc pays the higher dividend (2.45%). Which is the better fit depends on your goals.
| MRK | NTES | |
|---|---|---|
Market Cap | $366.28B | $76.85B |
Sector | Health | Media |
52-Week High | $156.43 | $159.34 |
52-Week Low | $77.60 | $109.26 |
Enterprise Value | $413.04B | $52.59B |
Dividend Yield | 2.29% | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
NetEase (NTES) trades at $119.45, up 0.13% on the day, with a bearish technical signal from moving averages and mixed earnings performance including a Q2 2026 EPS miss. The company maintains strong profitability with a 27.88% net income margin and robust cash flow, though net cash flow turned negative in 2025. Recent news highlights dividend growth and international expansion efforts amid competitive pressures.
The stock presents a valuation opportunity with a P/E of 15.93 below sector averages, supported by an 81.82% analyst buy rating. Key risks include earnings volatility and heavy investing outflows, but solid fundamentals and global growth initiatives offer long-term upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
